Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchAdintrevimabAdintrevimab (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
Adintrevimab for COVID-19
2 studies from 32 scientists
2,483 patients in 1 country
Statistically significant lower risk for hospitalization and cases.
2 studies (both from the same team) show statistically significant improvements.
COVID-19 Adintrevimab studies. Feb 2024. c19early.org
0 0.5 1 1.5+ All studies 43% Mortality 43% Hospitalization 83% Cases 71% RCTs 43% RCT mortality 43% Prophylaxis 43% Favorsadintrevimab Favorscontrol
mAb use may create new variants that spread globally Focosi, Leducq, and may be associated with prolonged viral loads, clinical deterioration, and immune escape Choudhary, Günther, Leducq. Submit updates/corrections.
Jun 13
2023
Ison et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofad314 Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)
75% fewer symptomatic cases (p=0.03). PEP RCT 351 patients, showing lower COVID-19 cases with adintrevimab. The PrEP trial is listed separately [Ison].
Jun 13
2023
Ison et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofad314 Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)
84% lower hospitalization (p=0.07) and 70% fewer symptomatic cases (p<0.0001). PrEP RCT 1480 patients, showing lower COVID-19 cases with adintrevimab. The PEP trial is listed separately [Ison].
Jan 24
2023
Zumbrun et al., Antimicrobial Agents and Chemotherapy, doi:10.1128/aac.01353-22 Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19
Hamster and monkey study showing dose-dependent protection against SARS-CoV-2 infection with prophylactic administration of a single dose of adintrevimab.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit